We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
FLT‐3 mutation maybe an inferior predictor of daratumumab therapy in acute myeloid leukemia patients relapsed after allogeneic stem cell transplantation.
- Authors
Xue, Song; Huang, Wenqiu; Zhang, Yongping; Liu, Fuhong; Hao, Qi; Hu, Jiajun; Yuan, Lei; Wang, Jingbo
- Abstract
The article examines the efficacy of daratumumab in treating relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (alloHSCT), focusing on its limited effectiveness, particularly in patients with Fms-like tyrosine kinase 3 (FLT-3) mutations. Topics discussed include treatment outcomes, safety profiles, and the potential role of daratumumab in bridging to further therapy in AML management post-alloHSCT.
- Subjects
HEMATOPOIETIC stem cell transplantation; FLOW cytometry; POLYMERASE chain reaction; SALVAGE therapy; MONOCLONAL antibodies; BONE marrow diseases; DRUG efficacy; GENETIC mutation; DISEASE relapse; LYMPHOBLASTIC leukemia; OVERALL survival; INTRAVENOUS injections
- Publication
International Journal of Laboratory Hematology, 2024, Vol 46, Issue 4, p741
- ISSN
1751-5521
- Publication type
Article
- DOI
10.1111/ijlh.14275